VOLABIOS

VOLABIOS aims to transform the early detection and clinical management of schizophrenia (SZ) by leveraging innovative and real-time spectrograph technology to certify that volatile organic compounds (VOCs) can be utilized as non-invasive and cost-effective biomarkers for the early detection of the disease. Underscoring the urgent need for accurate, accessible diagnostic tools, VOLABIOS will conduct large-scale prospective clinical studies involving 3,692 participants across six European centres and a blind validation cohort of 1,000 subjects.